{"doc_id": "32871238", "type of study": "Therapy", "title": "", "abstract": "\"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study\".\nThe vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome.\nCalcifediol can rapidly increase serum 25OHD concentration.\nWe therefore evaluated the effect of calcifediol treatment, on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19.\nParallel pilot randomized open label, double-masked clinical trial.\nUniversity hospital setting (Reina Sofia University Hospital, C\u00f3rdoba Spain.) PARTICIPANTS: 76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1).\nAll hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 h on the first day, and 200 mg every 12 h for the following 5 days), azithromycin (500 mg orally for 5 days.\nEligible patients were allocated at a 2 calcifediol:1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol (0.532 mg), or not.\nPatients in the calcifediol treatment group continued with oral calcifediol (0.266 mg) on day 3 and 7, and then weekly until discharge or ICU admission.\nOutcomes of effectiveness included rate of ICU admission and deaths.\nOf 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50 %) p value X2 Fischer test p < 0.001.\nUnivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95 %CI 0.002-0.17).\nMultivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension and T2DM): 0.03 (95 %CI: 0.003-0.25).\nOf the patients treated with calcifediol, none died, and all were discharged, without complications.\nThe 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged.\nOf the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.\nOur pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19.\nCalcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.\nCopyright \u00a9 2020 The Authors.\nPublished by Elsevier Ltd.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 165}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 170, "end": 178}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 148}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 133}, {"term": "COVID-19 infection", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 157}, {"term": "acute respiratory infection", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 207}, {"term": "positive SARS-CoV-2 PCR with CURB65 severity scale", "negation": "affirmed", "UMLS": {}, "start": 274, "end": 324}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 16}, {"term": "ICU", "negation": "negated", "UMLS": {}, "start": 42, "end": 45}, {"term": "admitted", "negation": "negated", "UMLS": {}, "start": 60, "end": 68}, {"term": "hospitalization", "negation": "affirmed", "UMLS": {}, "start": 225, "end": 240}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "\" Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19 : A pilot randomized clinical study \" .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 165}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 170, "end": 178}], "Intervention": [{"term": "calcifediol treatment", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 33}, {"term": "best available therapy", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 60}, {"term": "best available therapy", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 60}], "Outcome": [{"term": "intensive care unit admission", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 123}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 137}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "Calcifediol can rapidly increase serum 25OHD concentration .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Calcifediol", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11}], "Outcome": [{"term": "serum 25OHD concentration", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 58}], "Observation": [{"term": "rapidly increase", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 32}], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "We therefore evaluated the effect of calcifediol treatment , on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19 .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 148}], "Intervention": [{"term": "calcifediol treatment", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 58}], "Outcome": [{"term": "Intensive Care Unit Admission", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 93}, {"term": "Mortality rate", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 112}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Parallel pilot randomized open label , double-masked clinical trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "SETTING", "Text": "University hospital setting ( Reina Sofia University Hospital , C\u00f3rdoba Spain . ) PARTICIPANTS : 76 consecutive patients hospitalized with COVID-19 infection , clinical picture of acute respiratory infection , confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale ( recommending hospital admission in case of total score > 1 ) .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 133}, {"term": "COVID-19 infection", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 157}, {"term": "acute respiratory infection", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 207}, {"term": "positive SARS-CoV-2 PCR with CURB65 severity scale", "negation": "affirmed", "UMLS": {}, "start": 274, "end": 324}], "Intervention": [], "Outcome": [{"term": "hospital", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PROCEDURES", "Text": "All hospitalized patients received as best available therapy the same standard care , ( per hospital protocol ) , of a combination of hydroxychloroquine ( 400 mg every 12 h on the first day , and 200 mg every 12 h for the following 5 days ) , azithromycin ( 500 mg orally for 5 days .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 16}], "Intervention": [{"term": "combination of hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 152}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PROCEDURES", "Text": "Eligible patients were allocated at a 2 calcifediol : 1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol ( 0.532 mg ) , or not .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "oral calcifediol", "negation": "negated", "UMLS": {}, "start": 142, "end": 158}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PROCEDURES", "Text": "Patients in the calcifediol treatment group continued with oral calcifediol ( 0.266 mg ) on day 3 and 7 , and then weekly until discharge or ICU admission .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "calcifediol treatment", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 37}, {"term": "calcifediol", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 27}], "Outcome": [{"term": "discharge", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 137}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PROCEDURES", "Text": "Outcomes of effectiveness included rate of ICU admission and deaths .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "rate of ICU admission and deaths", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 67}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Of 50 patients treated with calcifediol , one required admission to the ICU ( 2 % ) , while of 26 untreated patients , 13 required admission ( 50 % ) p value X2 Fischer test p < 0.001 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "calcifediol", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 39}, {"term": "untreated", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 107}], "Outcome": [{"term": "admission to the ICU", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 75}, {"term": "admission", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 64}], "Observation": [], "Count": [{"term": "patients", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 14}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 45}, {"term": "2 %", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 81}, {"term": "13", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 121}, {"term": "50 %", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 147}]}, "Evidence Propositions": [{"Intervention": "calcifediol", "Observation": "", "Count": "2 %", "Outcome": "admission to the ICU"}, {"Intervention": "untreated", "Observation": "", "Count": "13", "Outcome": "admission"}]}, {"Section": "RESULTS", "Text": "Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment : 0.02 ( 95 % CI 0.002-0.17 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Calcifediol treatment", "negation": "negated", "UMLS": {}, "start": 61, "end": 82}, {"term": "without Calcifediol", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 109}], "Outcome": [{"term": "Univariate Risk Estimate Odds Ratio for ICU", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 43}], "Observation": [{"term": "0.02", "negation": "negated", "UMLS": {}, "start": 122, "end": 126}], "Count": []}, "Evidence Propositions": [{"Intervention": "Calcifediol treatment", "Observation": "0.02", "Outcome": "Univariate Risk Estimate Odds Ratio for ICU", "Count": ""}, {"Intervention": "without Calcifediol", "Observation": "0.02", "Outcome": "Univariate Risk Estimate Odds Ratio for ICU", "Count": ""}]}, {"Section": "RESULTS", "Text": "Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU ( adjusting by Hypertension and T2DM ) : 0.03 ( 95 % CI : 0.003-0.25 ) .", "Evidence Elements": {"Participant": [{"term": "ICU", "negation": "negated", "UMLS": {}, "start": 42, "end": 45}], "Intervention": [{"term": "Calcifediol treatment", "negation": "negated", "UMLS": {}, "start": 63, "end": 84}, {"term": "Calcifediol treatment", "negation": "negated", "UMLS": {}, "start": 63, "end": 84}], "Outcome": [{"term": "Estimate Odds Ratio for ICU", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 45}], "Observation": [{"term": "0.03", "negation": "negated", "UMLS": {}, "start": 163, "end": 167}], "Count": []}, "Evidence Propositions": [{"Intervention": "Calcifediol treatment", "Observation": "0.03", "Outcome": "Estimate Odds Ratio for ICU", "Count": ""}]}, {"Section": "RESULTS", "Text": "Of the patients treated with calcifediol , none died , and all were discharged , without complications .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "calcifediol", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 40}], "Outcome": [{"term": "died", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 52}, {"term": "discharged", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 78}], "Observation": [], "Count": [{"term": "none", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 47}, {"term": "all", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 62}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The 13 patients not treated with calcifediol , who were not admitted to the ICU , were discharged .", "Evidence Elements": {"Participant": [{"term": "admitted", "negation": "negated", "UMLS": {}, "start": 60, "end": 68}], "Intervention": [{"term": "calcifediol", "negation": "negated", "UMLS": {}, "start": 33, "end": 44}], "Outcome": [], "Observation": [], "Count": [{"term": "13 patients", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Of the 13 patients admitted to the ICU , two died and the remaining 11 were discharged .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "admitted to the ICU", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 38}, {"term": "died", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 49}], "Observation": [], "Count": [{"term": "13 patients", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 18}, {"term": "two", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 44}, {"term": "remaining", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 67}, {"term": "11", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 70}]}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D , a main metabolite of vitamin D endocrine system , significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19 .", "Evidence Elements": {"Participant": [{"term": "hospitalization", "negation": "affirmed", "UMLS": {}, "start": 225, "end": 240}], "Intervention": [{"term": "high dose of Calcifediol or 25-hydroxyvitamin D", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 101}], "Outcome": [{"term": "need for ICU treatment", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 202}], "Observation": [{"term": "significantly reduced", "negation": "affirmed", "UMLS": {}, "start": 154, "end": 175}], "Count": []}, "Evidence Propositions": [{"Intervention": "high dose of Calcifediol or 25-hydroxyvitamin D", "Observation": "significantly reduced", "Outcome": "need for ICU treatment", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "Calcifediol seems to be able to reduce severity of the disease , but larger trials with groups properly matched will be required to show a definitive answer .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 The Authors .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}